12:00 AM
 | 
Feb 21, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

MDV3100: Updated Phase I/II data

Updated data from an open-label, dose-escalation, U.S. Phase I/II trial in 140 patients who received 30-600 mg/day MDV3100 showed that median time to PSA progression, defined as a >25% increase in PSA from baseline, was 316 days for chemotherapy-experienced patients (n=75) and not yet reached for chemotherapy-naïve patients (n=65). Median time to...

Read the full 238 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >